{
    "Trade/Device Name(s)": [
        "Xpert Xpress CoV-2 plus",
        "Xpert\u00ae Xpress CoV-2 plus",
        "Xpert Xpress CoV-2 plus test"
    ],
    "Submitter Information": "Cepheid",
    "510(k) Number": "K230440",
    "Predicate Device Reference 510(k) Number(s)": [
        "K211079"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QQX",
        "OOI"
    ],
    "Summary Letter Date": "September 1, 2023",
    "Summary Letter Received Date": "September 12, 2023",
    "Submission Date": "February 17, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.3981"
    ],
    "Regulation Name(s)": [
        "Device To Detect And Identify Nucleic Acid Targets In Respiratory Specimens From Microbial Agents That Cause The SARS-CoV-2 Respiratory Infection And Other Microbial Agents When In A Multi-Target Test"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology",
        "genetic molecular"
    ],
    "Analyte(s)": [
        "SARS-CoV-2 RNA (targets: E, N2, RdRP genes)"
    ],
    "Specimen Type(s)": [
        "Nasopharyngeal swab",
        "Anterior nasal swab"
    ],
    "Specimen Container(s)": [
        "Nylon flocked swab",
        "Copan UTM",
        "BD Universal Viral Transport Kit",
        "Copan eNAT",
        "Remel M4RT",
        "Remel M5",
        "Viral transport medium",
        "Universal Transport Medium"
    ],
    "Instrument(s)/Platform(s)": [
        "GeneXpert Dx System",
        "GeneXpert Infinity-48s",
        "GeneXpert Infinity-80"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time RT-PCR",
        "Qualitative nucleic acid amplification"
    ],
    "Methodologies": [
        "RT-PCR",
        "Nucleic acid extraction",
        "Molecular detection"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Reagent",
        "Cartridge",
        "Platform"
    ],
    "Document Summary": "FDA 510(k) summary for Cepheid Xpert Xpress CoV-2 plus RT-PCR assay for SARS-CoV-2 RNA detection in nasopharyngeal and anterior nasal swab specimens.",
    "Indications for Use Summary": "Qualitative detection of SARS-CoV-2 RNA in nasopharyngeal and anterior nasal swab specimens from symptomatic individuals as an aid in COVID-19 diagnosis, used in conjunction with other clinical, epidemiologic, and laboratory findings.",
    "fda_folder": "Microbiology"
}